Trial, Multicenter [resa]
Uterine [bpoc]
Safety [hcpp]
Raloxifene [orch, phsu]
Continuous [idcn]
Combined [qlco]
Hormone replacement therapy [topp]
Containing [ftcn]
Estradiol [horm, phsu, strd]
Norethisterone acetate [horm, phsu, strd]
Objective [inpr]
Uterine [bpoc]
effects [qlco]
mg% [qnco]
Raloxifene [orch, phsu]
Continuous [idcn]
Combined [qlco]
Hormone replacement therapy [topp]
Preparation [ftcn]
mg% [qnco]
17beta estradiol [horm, phsu, strd]
mg% [qnco]
Norethisterone acetate [horm, phsu, strd]
Duration [tmco]
months [tmco]
Design [acty]
DOUBLE BLIND [resa]
Trial [resa]
setting [ftcn]
Europe [geoa]
Israel [geoa]
South Africa [geoa]
Asymptomatic [fndg]
postmenopausal [tmco]
Women [popg]
risk factors [qnco]
Osteoporosis [dsyn]
Cardiovascular disease [dsyn]
endometrium thickness [qnco]
One Thousand [qnco]
Eight [qnco]
Women [popg]
Six [qnco]
Core [spco]
Continue [idcn]
Six [qnco]
Extension [ftcn]
Methods [inpr]
Randomization [resa]
Raloxifene [orch, phsu]
Continuous [idcn]
Combined [qlco]
Hormone replacement therapy [topp]
Patients [podg]
Assessor [prog]
Blinded [resa]
treatment [ftcn]
Main [qlco]
Measure [qnco]
frequency [qnco]
Vaginal Bleeding [patf]
Spotting [patf]
Record [inpr]
diary [inpr]
endometrium thickness [qnco]
Uterine [bpoc]
Measured [qlco]
transvaginal sonography [diap]
baseline [bodm]
months [tmco]
Six [qnco]
months [tmco]
therapy [ftcn]
Raloxifene [orch, phsu]
Women [popg]
Raloxifene [orch, phsu]
Reporting [hlca]
Vaginal Bleeding [patf]
Spotting [patf]
???lead [elii, hops]
Phase [tmco]
Increased [qnco]
Continuous [idcn]
Combined [qlco]
Hormone replacement therapy [topp]
Group [idcn]
Raloxifene [orch, phsu]
treatment [ftcn]
baseline [bodm]
End Point [qlco]
endometrium thickness [qnco]
P NOS [aapp, imft]
Continuous [idcn]
combined treatment [topp]
Hormone replacement therapy [topp]
Value [qnco]
P NOS [aapp, imft]
Compared [acty]
Raloxifene [orch, phsu]
endometrium thickness [qnco]
Women [popg]
Continuous [idcn]
Combined [qlco]
Hormone replacement therapy [topp]
Increased [qnco]
End Point [qlco]
3 5 [qnco]
1-7 [gngm]
baseline [bodm]
P NOS [aapp, imft]
Raloxifene [orch, phsu]
Group [idcn]
trend [tmco]
Decrease [qlco]
baseline [bodm]
Uterine [bpoc]
P NOS [aapp, imft]
Continuous [idcn]
Combined [qlco]
Hormone replacement therapy [topp]
Group [idcn]
Uterine [bpoc]
P NOS [aapp, imft]
Compound [qlco]
Uterine [bpoc]
End Point [qlco]
Reach [orgf]
Statistical Significance [qnco]
P NOS [aapp, imft]
statistically significant [qnco]
treatment [ftcn]
Group [idcn]
Sustained [ftcn]
Parameters [fndg]
Extension [ftcn]
Discontinuation [hlca]
adverse events [fndg]
P NOS [aapp, imft]
Raloxifene [orch, phsu]
Group [idcn]
months [tmco]
Compared [acty]
Continuous [idcn]
Combined [qlco]
Hormone replacement therapy [topp]
months [tmco]
Raloxifene [orch, phsu]
treatment [ftcn]
???lead [elii, hops]
vaginal spotting [fndg]
Bleeding [patf]
Increased thickness [fndg]
Endometrial [spco]
Uterine [bpoc]
treatment [ftcn]
discontinuations [hlca]
Asymptomatic [fndg]
Women [popg]
Receive [qlco]
treatment [ftcn]
PREVENT [phsu]
postmenopausal [tmco]
Health [idcn]
Risks [qlco]
